Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
Skin Therapy Lett
; 25(3): 1-4, 2020 May.
Article
em En
| MEDLINE
| ID: mdl-32510689
ABSTRACT
Psoriasis is a common, chronic, immune-mediated, inflammatory disorder with significant skin manifestations and substantial burden on quality of life. Interleukin-23 is a key regulator of different effector cytokines and plays a cardinal role in the pathogenesis of psoriasis. The monoclonal antibody, risankizumab, inhibits this key cytokine and thus prevents the downstream inflammatory cascade. This article aims to review our current understanding of risankizumab through the analysis of the various clinical trials.
Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Subunidade p19 da Interleucina-23
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Revista:
Skin Therapy Lett
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Reino Unido